82 related articles for article (PubMed ID: 20144978)
1. Imprecision of tumour biomarker measurements on Roche Modular E170 platform fulfills desirable goals derived from biological variation.
Dolci A; Scapellato L; Mozzi R; Panteghini M
Ann Clin Biochem; 2010 Mar; 47(Pt 2):171-3. PubMed ID: 20144978
[TBL] [Abstract][Full Text] [Related]
2. [National external quality assessment and comparability of assays for tumor markers measurements].
Zhang JT; Zhang CB; Ma R; Zhao HJ; Wang J; Wang ZG; Chen WX
Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):993-7. PubMed ID: 20646652
[TBL] [Abstract][Full Text] [Related]
3. Serum tumour markers in patients with chronic kidney disease.
Xiaofang Y; Yue Z; Xialian X; Zhibin Y
Scand J Clin Lab Invest; 2007; 67(6):661-7. PubMed ID: 17852811
[TBL] [Abstract][Full Text] [Related]
4. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
5. [The determination of medical reference values for tumor markers in cerebrospinal fluid].
Shi Q; Pu CQ; Wu WP; Huang XS; Yu SY; Tian CL; Cao XT
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(5):355-6. PubMed ID: 19563718
[TBL] [Abstract][Full Text] [Related]
6. Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study.
Bjerner J; Høgetveit A; Wold Akselberg K; Vangsnes K; Paus E; Bjøro T; Børmer OP; Nustad K
Scand J Clin Lab Invest; 2008; 68(8):703-13. PubMed ID: 18609108
[TBL] [Abstract][Full Text] [Related]
7. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
8. Biological variation and reference change values of CA 19-9, CEA, AFP in serum of healthy individuals.
Erden G; Barazi AO; Tezcan G; Yildirimkaya MM
Scand J Clin Lab Invest; 2008; 68(3):212-8. PubMed ID: 17926198
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
Li CS; Cheng BC; Ge W; Gao JF
Int J Clin Pract; 2007 Mar; 61(3):444-8. PubMed ID: 17313612
[TBL] [Abstract][Full Text] [Related]
10. Effect of freeze-thaw cycles on serum measurements of AFP, CEA, CA125 and CA19-9.
Gao YC; Yuan ZB; Yang YD; Lu HK
Scand J Clin Lab Invest; 2007; 67(7):741-7. PubMed ID: 17852813
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of analytical methods and workflow performance of the Architect ci8200 integrated serum/plasma analyzer system.
Hubl W; Zogbaum M; Boyd JC; Savory J; Schubert M; Meyer D; Demant T
Clin Chim Acta; 2005 Jul; 357(1):43-54. PubMed ID: 15963793
[TBL] [Abstract][Full Text] [Related]
12. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
13. Influence of cardiopulmonary resuscitation on levels of tumour markers.
Berent R; Auer J; Porodko M; Lamm G; Weber T; Wimmer E; Seier J; Aspöck G; Eber B
Eur J Cancer Care (Engl); 2006 Jul; 15(3):252-6. PubMed ID: 16882121
[TBL] [Abstract][Full Text] [Related]
14. CEA, TPA, CA 19-9, SCC and CYFRA at diagnosis and in the follow-up of anal canal tumors.
Indinnimeo M; Reale MG; Cicchini C; Stazi A; Fiori E; Izzo P
Int Surg; 1997; 82(3):275-9. PubMed ID: 9372374
[TBL] [Abstract][Full Text] [Related]
15. Results from a multicenter evaluation of the 4th generation Elecsys Troponin T assay.
Hermsen D; Apple F; Garcia-Beltràn L; Jaffe A; Karon B; Lewandrowski E; Mühlbacher A; Müller R; Ordóñez J; Pagani F; Panteghini M; Plecko T; Jarausch J
Clin Lab; 2007; 53(1-2):1-9. PubMed ID: 17323819
[TBL] [Abstract][Full Text] [Related]
16. [Recrudescence of prostate cancer with low serum level of PSA and high serum level of CEA and CA19-9: a case report].
Yokoyama S; Fukuhara S; Imazu T; Hara T; Yamaguchi S; Adachi S
Hinyokika Kiyo; 2007 Jul; 53(7):485-7. PubMed ID: 17702183
[TBL] [Abstract][Full Text] [Related]
17. Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
Ogawa A; Yoshida A; Kanda T; Sugihara S; Suzuki T; Tamura J; Kobayashi I; Nakazato Y
J Med; 2000; 31(1-2):101-10. PubMed ID: 10998759
[TBL] [Abstract][Full Text] [Related]
18. Serum tumor markers in patients on dialysis and kidney transplantation.
Lye WC; Tambyah P; Leong SO; Lee EJ
Adv Perit Dial; 1994; 10():109-11. PubMed ID: 7528056
[TBL] [Abstract][Full Text] [Related]
19. Investigating the Current Harmonization Status of Tumor Markers Using Global External Quality Assessment Programs: A Feasibility Study.
van Rossum HH; Holdenrieder S; Ballieux BEPB; Badrick TC; Yun YM; Zhang C; Patel D; Thelen M; Song J; Wojtalewicz N; Unsworth N; Vesper HW; Cui W; Ramanathan LV; Sturgeon C; Meng QH
Clin Chem; 2024 Apr; 70(4):669-679. PubMed ID: 38385453
[TBL] [Abstract][Full Text] [Related]
20. The clinical significance in healthy men of the association between obesity related plasma hemodilution and tumor marker concentration.
Chang IH; Ahn SH; Han JH; Kim TH; Kim YS; Myung SC
J Urol; 2009 Feb; 181(2):567-72; discussion 572-3. PubMed ID: 19084848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
